$4.73

-0.15 (-3.07%)

10/7/2008 3:45 PM

Nymox Pharmaceutical Corp (NYMX)

CAPS Rating:

A biopharmaceutical company with three proprietary products on the market and a R&D of drug & diagnostic products in development for the treatment of enlarged prostate, Alzheimer's disease contamination of food and drink products and bacterial infections.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating NYMX

Add Stock to Watchlist

What the Community Thinks

Total Members

31 Outperforms

28 Underperforms

All-Stars

5 Outperforms

14 Underperforms

Members bullish on NYMX are also bullish on:

Members bearish on NYMX are also bearish on:

Ticker Tags

Micro Cap (4824), Rule Breakers Universe (161), Diagnostic Substances (53)
Suggest a tag

Nymox Pharmaceutical Corp At A Glance

Current Price:	$4.73
Last Trade Time:	10/7/2008 3:45 PM
Open:	$5.00
Previous Close:	$4.88
Daily Range:	$4.70 - $5.10
52-Week Range:	$2.83 - $6.86
Volume:	21,535
Market Cap:	$145.52M
P/E Ratio:	0.00
Compare Our Special Broker Offers!

Stock Trends

NYMX VS S&P 500 (SPY)

News & Discussion Boards

Sorry no news articles available for NYMX.

Top Bull Pitch

Recs

2 Nymox Pharmaceutical Corp (NYMX)

Avatar Voyt608 (< 20) Submitted: 4/12/07 9:07 AM

Non estrogenic treatment for benign proatatic hyperplasia with proven efficacy ih reducing symptoms such as frepuent voiding, urgency, nocturia, dripping etc. No significant side effects and a 30% reduction in prostate size in late trials. Tremendous market potential.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

2 Nymox Pharmaceutical Corp (NYMX)

Avatar NeroSagetrade (52.11) Submitted: 10/11/07 6:53 PM

There are far too many of these types of pharmaceutical companies out there...plenty of promise, huge valuation and failure to deliver. Nymox currently has one...yes..only one drug currently in late stage trials to treat enlarging prostates. The company has managed just 450k in sales for the entire ...More

Replies: 0 | Reply | Permalink

CAPS Members

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 11 : 1 2 3 Next »

Recs 0 (NYMX) blade5adj (88.63) Submitted: 6/25/08 5:08 AM : Start Price: $4.14 NYMX Score: -38.31 Solvency and significantly overvalued Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (NYMX) zzlangerhans (98.62) Submitted: 6/06/08 3:50 AM : Start Price: $5.30 NYMX Score: -21.35 CAPS deleted my intial comment on this stinker of a company, probably because I compared the smell of the company to that of a dead prostitute. Perhaps the same crybaby will complain again, let's see. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (NYMX) GershwinStephen (91.22) Submitted: 1/30/08 5:33 PM : Start Price: $5.07 NYMX Score: 18.31 acquisiton, Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 2 (NYMX) NeroSagetrade (52.11) Submitted: 10/11/07 6:53 PM : Start Price: $6.25 NYMX Score: -11.34 There are far too many of these types of pharmaceutical companies out there...plenty of promise, huge valuation and failure to deliver. Nymox currently has one...yes..only one drug currently in late stage trials to treat enlarging prostates. The company has managed just 450k in sales for the entire year yet is valued at over 183 million dollars. Losses are increasing, and based on my estimates, they dont even have enough cash to get out of Q1 2008! Over 400 times price to sales, 58 times book, and increasing losses..where's the buy button?!! If you look historically at the long-term chart, this falls mercilessly for 2-3 months after every large rise. Nero Sagetrade Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 2 (NYMX) Voyt608 (< 20) Submitted: 4/12/07 9:07 AM : Start Price: $5.61 NYMX Score: 14.72 Non estrogenic treatment for benign proatatic hyperplasia with proven efficacy ih reducing symptoms such as frepuent voiding, urgency, nocturia, dripping etc. No significant side effects and a 30% reduction in prostate size in late trials. Tremendous market potential. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 11 : 1 2 3 Next »

Wall Street

There are no Wall Street tracker picks.

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.